HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.

Abstract
A devastating disease spread by mosquitoes with high-efficiency, malaria imposes an enormous burden for which no licensed vaccine currently exists. Although the genome complexity of the parasite has made vaccine development tenuous, an effective malaria vaccine would be a valuable tool for control, elimination and eventual eradication. The Plasmodium serine repeat antigen 5 (SERA5) is an abundant asexual blood stage antigen that does not show any antigenic variation and exhibits limited polymorphism, making it a suitable vaccine candidate. Identified by comparing the IgG status of people in endemic areas with protective immunity and those with malaria symptoms, the vaccine potential of the N-terminal domain of Plasmodium falciparum SERA5 is also strongly supported by experimental data and immune responses both measured in vitro and in animal challenge models. The current understanding of SERA5 will be presented, particularly in relation to its path towards clinical development. The review highlights lessons learned and sorts out issues upon which further research efforts are needed.
AuthorsNirianne Marie Q Palacpac, Nobuko Arisue, Takahiro Tougan, Ken J Ishii, Toshihiro Horii
JournalVaccine (Vaccine) Vol. 29 Issue 35 Pg. 5837-45 (Aug 11 2011) ISSN: 1873-2518 [Electronic] Netherlands
PMID21718740 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
CopyrightCopyright © 2011 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Protozoan
  • Antigens, Protozoan
  • Malaria Vaccines
  • serine repeat antigen 5, Plasmodium falciparum
Topics
  • Adolescent
  • Adult
  • Animals
  • Antibodies, Protozoan (blood)
  • Antigens, Protozoan (genetics, immunology)
  • Child
  • Child, Preschool
  • Clinical Trials, Phase I as Topic
  • Humans
  • Infant
  • Malaria Vaccines
  • Malaria, Falciparum (immunology, prevention & control)
  • Plasmodium falciparum (growth & development, immunology)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: